Physician

Devin Dhiren Mehta, M.D., M.A.

According to 2025 Medicare claims, Devin Mehta, M.D., M.A. (NPI: 1922361344) practices advanced heart failure and transplant cardiology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is ENDEAVOR HEALTH MEDICAL GROUP (NPI: 1497701882; TIN: 363738206) and primary practice location at 60056-1151.

Mehta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,209 traditional Medicare patients, billed 3,007 HCPCS/CPT codes, and received $212,609 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 5,522 prescription claims across 579 beneficiaries totaling $3,505,276 in drug costs, led by Vyndamax (Tafamidis). DME data shows 162 claims. Open Payments data shows 42 records totaling $891. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $43,795 to $212,609. Similarly, Part D prescription costs have moved sharply higher in recent years, from $18,838 to $3,505,276. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	303	595	$43,795
2020	1,349	2,512	$138,024
2021	1,892	3,634	$210,565
2022	1,772	3,450	$217,674
2023	1,772	3,862	$244,255
2024	1,209	3,007	$212,609

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	37	375	$18,838
2016	N/R	21	$259
2017	N/R	34	$1,548
2018	N/R	N/R	N/R
2019	46	89	$5,437
2020	162	841	$279,940
2021	322	1,944	$503,212
2022	430	3,111	$1,136,969
2023	541	4,259	$1,836,715
2024	579	5,522	$3,505,276

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	83	$3,513
2022	N/R	75	$3,774
2023	N/R	181	$12,212
2024	N/R	162	$9,692

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	218	270	$145
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	260	336	$102
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	220	394	$67
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	284	368	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	265	288	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	53	1,950	$1,492,255
Eliquis	Apixaban	369	24,140	$459,676
Entresto	Sacubitril/Valsartan	318	21,317	$437,277
Jardiance	Empagliflozin	294	20,985	$398,222
Vyndaqel	Tafamidis Meglumine	13	390	$282,748

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	41	$5,165
J2260	Injection, milrinone lactate, 5 mg	N	N/R	40	$1,929
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	20	$1,470
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	41	$786
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	20	$342

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$891	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Devin Dhiren Mehta, M.D., M.A.?

Tedicare shows public-source Medicare data for Devin Dhiren Mehta, M.D., M.A. (NPI 1922361344), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Devin Dhiren Mehta, M.D., M.A. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Devin Dhiren Mehta, M.D., M.A.?

Devin Dhiren Mehta, M.D., M.A. is linked to ENDEAVOR HEALTH MEDICAL GROUP (billing NPI 1497701882) in the available physician profile data.

Does Devin Dhiren Mehta, M.D., M.A. have Open Payments data?

Devin Dhiren Mehta, M.D., M.A. has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.